Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRX to expedite clinical trials after opening state-of-the-art lab

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers
The facility was opened on time and within budget

VolitionRx Ltd (NYSEMKT:VNRX) has opened a new research and development facility in Belgium this week.

The US-listed European cancer diagnostics group said the purpose-built laboratory would enable it to increase capacity to carry out clinical trials and to expand its scientific team.

A more modern lab and a bigger lab team should lead to trials taking less time.

WATCH a video showcasing the start-of-the art lab

READ the VolitionRX investment case

"Our capacity to run large clinical trials has increased significantly with this five-fold increase in laboratory space. This will facilitate large scale manual and automated robotic testing. We will now have the ability to work on several large trials at the same time, namely: the front-line screening colorectal cancer tests and  lung, prostate and pancreatic cancer," said Dr Marielle Herzog, Research and Development Director of Volition.

Volition's Belgian arm acquired the 19,000 square foot property for €1.2mln – about US$1.29mln.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.

Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile View Profile

VolitionRx Timeline

Big Picture
May 11 2017
April 11 2017

Related Articles

Netscientific has its thumbs in a few clinical pies
March 31 2017
The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms
April 05 2017
The share placing follows a period of expansion that has seen it make two major acquisition
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use